JP2009501797A - 増強された眼神経保護／神経刺激 - Google Patents

増強された眼神経保護／神経刺激 Download PDF

Info

Publication number
JP2009501797A
JP2009501797A JP2008522862A JP2008522862A JP2009501797A JP 2009501797 A JP2009501797 A JP 2009501797A JP 2008522862 A JP2008522862 A JP 2008522862A JP 2008522862 A JP2008522862 A JP 2008522862A JP 2009501797 A JP2009501797 A JP 2009501797A
Authority
JP
Japan
Prior art keywords
factor
patient
macrolide
neuroprotective
neurostimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008522862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501797A5 (enExample
Inventor
ゴーラム・エー・ペイマン
Original Assignee
ミヌ・エル・エル・シー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミヌ・エル・エル・シー filed Critical ミヌ・エル・エル・シー
Priority claimed from PCT/US2006/027713 external-priority patent/WO2007011880A2/en
Publication of JP2009501797A publication Critical patent/JP2009501797A/ja
Publication of JP2009501797A5 publication Critical patent/JP2009501797A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Prostheses (AREA)
JP2008522862A 2005-07-18 2006-07-18 増強された眼神経保護／神経刺激 Pending JP2009501797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/183,355 US20070014760A1 (en) 2005-07-18 2005-07-18 Enhanced recovery following ocular surgery
US11/263,737 US20070015697A1 (en) 2005-07-18 2005-11-01 Enhanced ocular neuroprotection and neurostimulation
PCT/US2006/027713 WO2007011880A2 (en) 2005-07-18 2006-07-18 Enhanced ocular neuroprotection/neurostimulation

Publications (2)

Publication Number Publication Date
JP2009501797A true JP2009501797A (ja) 2009-01-22
JP2009501797A5 JP2009501797A5 (enExample) 2009-09-03

Family

ID=37661858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522862A Pending JP2009501797A (ja) 2005-07-18 2006-07-18 増強された眼神経保護／神経刺激

Country Status (8)

Country Link
US (4) US20070014760A1 (enExample)
EP (1) EP2074994A1 (enExample)
JP (1) JP2009501797A (enExample)
AT (1) ATE429914T1 (enExample)
BR (1) BRPI0612859A2 (enExample)
DE (1) DE602006006575D1 (enExample)
DK (1) DK1904056T3 (enExample)
ES (1) ES2326550T3 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524431A (ja) * 2012-07-27 2015-08-24 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 視神経損傷、眼虚血または眼の再灌流傷害を治療する方法
JP2016026229A (ja) * 2009-11-16 2016-02-12 エイチエムエフアールエイ ハンガリー リミテッド ライアビリティー カンパニーＨｍｆｒａ Ｈｕｎｇａｒｙ Ｌｉｍｉｔｅｄ Ｌｉａｂｉｌｉｔｙ Ｃｏｍｐａｎｙ Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用
JP2020523416A (ja) * 2017-06-15 2020-08-06 アジエンダ・オスペダリエロ−ウニベルシタリア・ディ・ボローニャ・ポリクリニコ・エス・オルソラ−マルピーギＡｚｉｅｎｄａ Ｏｓｐｅｄａｌｉｅｒｏ−Ｕｎｉｖｅｒｓｉｔａｒｉａ Ｄｉ Ｂｏｌｏｇｎａ Ｐｏｌｉｃｌｉｎｉｃｏ Ｓ．Ｏｒｓｏｌａ−Ｍａｌｐｉｇｈｉ 神経変性眼科学的病状の治療に使用する血清
CN113301915A (zh) * 2019-01-04 2021-08-24 加利福尼亚大学董事会 用于促进眼中的血管生成的组合物和方法
JP2022540291A (ja) * 2019-05-16 2022-09-15 沈陽福洋医薬科技有限公司 線維化を予防、緩和及び／又は治療するための薬物、組成製品及びその応用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027906A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
GB2438544A (en) * 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070237722A1 (en) * 2006-03-28 2007-10-11 Peyman Gholam A Neural conduit agent dissemination
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US8088789B2 (en) * 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN101557814B (zh) 2006-09-13 2015-05-20 万能医药公司 大环内酯化合物及它们的使用方法
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
BRPI0822405A8 (pt) * 2008-03-11 2018-06-05 Elixir Medical Corp Método para tratar uma condição ou doença oftálmica, composição farmacêutica, dispositivo para o uso intracorporal, método para inibir a proliferação celular, composto, e, método para fabricar um composto
CN105380947A (zh) * 2008-03-11 2016-03-09 万能医药公司 大环内酯化合物及它们的使用方法
EP2276420B1 (en) 2008-04-04 2021-10-06 Journey1, Inc. Device to treat an eye having an epithelium with a defect
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
ES2649890T3 (es) 2009-10-23 2018-01-16 Nexisvision, Inc. Enervación corneal para el tratamiento de dolor ocular
US9498385B2 (en) 2009-10-23 2016-11-22 Nexisvision, Inc. Conformable therapeutic shield for vision and pain
US8591025B1 (en) 2012-09-11 2013-11-26 Nexisvision, Inc. Eye covering and refractive correction methods for LASIK and other applications
US9395558B2 (en) 2010-10-25 2016-07-19 Nexisvision, Inc. Methods and apparatus to identify eye coverings for vision
US8678584B2 (en) 2012-04-20 2014-03-25 Nexisvision, Inc. Contact lenses for refractive correction
WO2012149056A1 (en) 2011-04-28 2012-11-01 Nexisvision, Inc. Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
ITRM20110233A1 (it) * 2011-05-10 2012-11-11 Univ Calabria Azitromicina, suoi sali o solvati farmaceuticamente accettabili per l?uso come neuroprotettori.
EP2734261B1 (en) 2011-07-18 2018-02-21 Mor-Research Applications Ltd. A device for adjusting the intraocular pressure
RU2494707C2 (ru) * 2011-12-23 2013-10-10 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Способ лечения открытоугольной глаукомы
CN104335104B (zh) 2012-04-20 2017-06-09 内希斯视觉股份有限公司 用于屈光矫正的接触透镜
US9465233B2 (en) 2012-04-20 2016-10-11 Nexisvision, Inc. Bimodular contact lenses
JP6310072B2 (ja) 2013-06-26 2018-04-11 ネクシスビジョン， インコーポレイテッド 屈折矯正のためのコンタクトレンズ
US9341864B2 (en) 2013-11-15 2016-05-17 Nexisvision, Inc. Contact lenses having a reinforcing scaffold
WO2015116559A1 (en) 2014-01-29 2015-08-06 Nexisvision, Inc. Multifocal bimodulus contact lenses
WO2018017594A1 (en) * 2016-07-18 2018-01-25 Baylor College Of Medicine Non-contact air esthesiometer
EP4121062A1 (en) * 2020-03-19 2023-01-25 Universität Rostock Josamycin for use in prevention and treatment of fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011813A2 (en) * 2003-07-30 2005-02-10 Minu, L.L.C. Treatment of ocular disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US634693A (en) * 1899-02-23 1899-10-10 Carnegie Steel Company Ltd Clamp for poles or columns.
FR900520A (fr) 1943-12-13 1945-07-02 Nouveau système de trusquin
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
EP0406791B1 (en) * 1989-07-05 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Aqueous liquid composition for external use
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5457182A (en) * 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6238799B1 (en) * 1996-02-09 2001-05-29 Surface Solutions Laboratories, Inc. Articles prepared from water-based hydrophilic coating compositions
PT880362E (pt) * 1996-02-13 2005-10-31 Searle & Co Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20030181692A1 (en) * 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6673807B1 (en) * 1998-04-06 2004-01-06 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
AU6526100A (en) * 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
ES2206363T3 (es) * 2000-04-07 2004-05-16 Laboratoire Medidom S.A. Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato.
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US6440942B1 (en) * 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
US6462026B1 (en) * 2001-02-16 2002-10-08 Enanta Pharmaceuticals, Inc. Bicyclic leucomycins
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6436906B1 (en) * 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040162315A1 (en) * 2002-07-23 2004-08-19 Hellberg Mark R. Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US10575605B2 (en) 2010-03-09 2020-03-03 F.D. Worldwide Merchandise Group, Inc. Jewelry stones set with prongs and invisible settings
US10328305B1 (en) 2016-06-06 2019-06-25 Joseph D Maresh Exercise machine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011813A2 (en) * 2003-07-30 2005-02-10 Minu, L.L.C. Treatment of ocular disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016026229A (ja) * 2009-11-16 2016-02-12 エイチエムエフアールエイ ハンガリー リミテッド ライアビリティー カンパニーＨｍｆｒａ Ｈｕｎｇａｒｙ Ｌｉｍｉｔｅｄ Ｌｉａｂｉｌｉｔｙ Ｃｏｍｐａｎｙ Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用
JP2015524431A (ja) * 2012-07-27 2015-08-24 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 視神経損傷、眼虚血または眼の再灌流傷害を治療する方法
JP2020523416A (ja) * 2017-06-15 2020-08-06 アジエンダ・オスペダリエロ−ウニベルシタリア・ディ・ボローニャ・ポリクリニコ・エス・オルソラ−マルピーギＡｚｉｅｎｄａ Ｏｓｐｅｄａｌｉｅｒｏ−Ｕｎｉｖｅｒｓｉｔａｒｉａ Ｄｉ Ｂｏｌｏｇｎａ Ｐｏｌｉｃｌｉｎｉｃｏ Ｓ．Ｏｒｓｏｌａ−Ｍａｌｐｉｇｈｉ 神経変性眼科学的病状の治療に使用する血清
CN113301915A (zh) * 2019-01-04 2021-08-24 加利福尼亚大学董事会 用于促进眼中的血管生成的组合物和方法
JP2022540291A (ja) * 2019-05-16 2022-09-15 沈陽福洋医薬科技有限公司 線維化を予防、緩和及び／又は治療するための薬物、組成製品及びその応用

Also Published As

Publication number Publication date
DK1904056T3 (da) 2009-08-10
ATE429914T1 (de) 2009-05-15
US20090143282A1 (en) 2009-06-04
EP2074994A1 (en) 2009-07-01
US20080102101A1 (en) 2008-05-01
US20070015697A1 (en) 2007-01-18
ES2326550T3 (es) 2009-10-14
US20070014760A1 (en) 2007-01-18
BRPI0612859A2 (pt) 2010-11-30
DE602006006575D1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
EP1904056B1 (en) Use of a macrolide to restore corneal sensation
JP2009501797A (ja) 増強された眼神経保護／神経刺激
Sanborn et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device
Sharif Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision
US7083802B2 (en) Treatment of ocular disease
US20080262415A1 (en) Enhanced wound healing
WO2007038453A2 (en) Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US20070071756A1 (en) Delivery of an agent to ameliorate inflammation
US20080003219A1 (en) Delivery of an ocular agent
US20080167600A1 (en) Device for delivery of an agent to the eye and other sites
Nguyen et al. Intravitreal sirolimus for the treatment of noninfectious uveitis: evolution through preclinical and clinical studies
PT1755616E (pt) Tratamento de condições patológicas oftálmicas
WO2005082380A1 (en) Heparin for the treatment of ocular pathologies
US20090136514A1 (en) Tetracyclines for Treating Ocular Diseases and Disorders
US20190247227A1 (en) Methods For Treatment Of Dry Eye And Other Acute Or Chronic Inflammatory Processes
US20060166956A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
JP2010522774A (ja) 血管新生眼疾患を治療するための方法
Rizzo et al. Safety results for geographic atrophy associated with age-related macular degeneration using subretinal cord blood platelet-rich plasma
US20050261243A1 (en) Antiprostaglandins for the treatment of ocular pathologies
Gote et al. Ocular implants in the clinic and under clinical investigation for ocular disorders
CN117279653A (zh) 用于治疗眼部疾病和病症的化合物
de Zea et al. Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy
Levison Noninfectious Uveitis: Systemic and Local Corticosteroids
Lockwood et al. Novel therapies and future directions

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120328

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918